Detalhe da pesquisa
1.
Specific Polo-Like Kinase 1 Expression in Nodular Lymphocyte-Predominant Hodgkin Lymphoma Suggests an Intact Immune Surveillance Program.
Am J Pathol
; 194(1): 165-178, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37923249
2.
TSG-6 as a biomarker to predict efficacy of human mesenchymal stem/progenitor cells (hMSCs) in modulating sterile inflammation in vivo.
Proc Natl Acad Sci U S A
; 111(47): 16766-71, 2014 Nov 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-25385603
3.
Autologous stem cell transplant in first remission for transformed indolent non-Hodgkin lymphoma: additional data to guide practice.
Br J Haematol
; 191(5): 663-665, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33065776
4.
Observation of lymphadenopathy, systemic symptoms, and treatment in suspected indolent cutaneous B-cell lymphomas.
Arch Dermatol Res
; 316(5): 199, 2024 May 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38775835
5.
Gemcitabine and liposomal doxorubicin (GemDox) for the treatment of relapsed and refractory T-cell lymphomas.
Leuk Lymphoma
; 65(3): 301-311, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38093530
6.
GATA-3-dependent Gene Transcription is Impaired upon HDAC Inhibition.
Clin Cancer Res
; 30(5): 1054-1066, 2024 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38165708
7.
Successful anti-tumor effects with two novel bifunctional chemotherapeutic compounds that combine a LAT1 substrate with cytotoxic moieties in aggressive T-cell lymphomas.
Leuk Res Rep
; 21: 100398, 2024.
Artigo
em Inglês
| MEDLINE | ID: mdl-38192502
8.
Post-infusion PD-1+CD8+CAR-T cells identify patients responsive to CD19-CAR-T therapy in non-Hodgkin's lymphoma.
Blood Adv
; 2024 Mar 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-38607381
9.
PTCL, NOS: An update on classification, risk-stratification, and treatment.
Front Oncol
; 13: 1101441, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36845711
10.
Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
Front Immunol
; 14: 1291259, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-38022633
11.
Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents.
Cancer Med
; 12(7): 8228-8237, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36653918
12.
A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma.
Cancers (Basel)
; 15(5)2023 Feb 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-36900230
13.
Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study.
J Hematol Oncol
; 16(1): 111, 2023 11 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37946255
14.
Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1,790 patients.
Am J Hematol
; 92(2): E15-E17, 2017 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-27813147
15.
Recent Advances in the Management of Relapsed and Refractory Peripheral T-Cell Lymphomas.
J Pers Med
; 12(6)2022 Jun 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-35743749
16.
Extranodal Natural Killer/T-Cell Lymphomas: Current Approaches and Future Directions.
J Clin Med
; 11(10)2022 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-35628826
17.
Outcomes of patients with diffuse large B-cell and high-grade B-cell lymphomas with synchronous CNS and systemic involvement at diagnosis treated with high-dose methotrexate and R-CHOP: a single-center retrospective study.
Ther Adv Hematol
; 13: 20406207221112900, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-35898434
18.
CD3e-immunotoxin spares CD62Llo Tregs and reshapes organ-specific T-cell composition by preferentially depleting CD3ehi T cells.
Front Immunol
; 13: 1011190, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36389741
19.
Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas.
Cancer Res Commun
; 2(12): 1727-1737, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36970721
20.
Feasibility of high-dose methotrexate administered on day 1 of (R)CHOP in aggressive non-Hodgkin lymphomas.
Blood Adv
; 6(2): 460-472, 2022 01 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-34788387